Top Markets
Coin of the day
Septerna Inc Septerna Inc

Septerna Inc

SEPN
Pozycja w akcjach #6851
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops... Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Cena akcji
$40.61
Ostatnia synchronizacja: 2026-08-27
Kapitalizacja rynkowa
$1.83B
Zmiana (1 dzień)
0.89%
Zmiana (1 rok)
230.70%
Kraj
US
Handel Septerna Inc (SEPN)

Kategoria

Historia stopy dywidendy dla Septerna Inc (SEPN)
Stopa dywidendy (TTM) dla Septerna Inc (symbol akcji: SEPN) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Septerna Inc (SEPN) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji